Literature DB >> 9477479

Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.

Z I Lobato1, B E Coupar, C P Gray, R Lunt, M E Andrew.   

Abstract

The role of individual viral proteins in the immune response to bluetongue virus (BTV) is not clearly understood. To investigate the contributions of the outer capsid proteins, VP2 and VP5, and possible interactions between them, these proteins were expressed from recombinant vaccinia viruses either as individual proteins or together in double recombinants, or with the core protein VP7 in a triple recombinant. Comparison of the immunogenicity of the vaccinia expressed proteins with BTV expressed proteins was carried out by inoculation of rabbits and sheep. Each of the recombinants was capable of stimulating an anti-BTV antibody response, although there was a wide range in the level of response between animals and species. Vaccinia-expressed VP2 was poorly immunogenic, particularly in rabbits. VP5, on the whole, stimulated higher ELISA titers in rabbits and sheep and in some animals in both species was able to stimulate virus neutralizing antibodies. When the protective efficacy of VP2 and VP5 was tested in sheep, vaccinia-expressed VP2, VP5 and VP2 + VP5 were protective, with the most consistent protection being in groups immunized with both proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9477479     DOI: 10.1016/s0165-2427(97)00084-6

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  15 in total

1.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

3.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

4.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

5.  Developing vaccines against foot-and-mouth disease and some other exotic viral diseases of livestock.

Authors:  David J Paton; Geraldine Taylor
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

6.  Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.

Authors:  Eva Calvo-Pinilla; Nicolás Navasa; Juan Anguita; Javier Ortego
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

7.  An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model.

Authors:  Guanggang Ma; Michael Eschbaumer; Abdelrahman Said; Bernd Hoffmann; Martin Beer; Nikolaus Osterrieder
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

8.  Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.

Authors:  Stefanie Kochinger; Nathalie Renevey; Martin A Hofmann; Gert Zimmer
Journal:  Vet Res       Date:  2014-06-13       Impact factor: 3.683

9.  Presence of Antibodies against Bluetongue Virus (BTV) in Sheep 5 to 7.5 Years after Vaccination with Inactivated BTV-8 Vaccines.

Authors:  Johanna Hilke; Heinz Strobel; Soeren Woelke; Melanie Stoeter; Katja Voigt; Bernd Moeller; Max Bastian; Martin Ganter
Journal:  Viruses       Date:  2019-06-08       Impact factor: 5.048

10.  Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.

Authors:  Verónica Martín; Elena Pascual; Miguel Avia; Lourdes Peña; Félix Valcárcel; Noemí Sevilla
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.